CanadaBis Completes Qualifying Transaction

About this update from Canadabis Capital, Inc.

[{"type":"text","content":"CanadaBis Completes Qualifying TransactionCALGARY, AB / ACCESSWIRE / April 26, 2019 / CanadaBis Capital Inc. (CANB.P: TSX-V) is pleased to announce that it has completed its previously announced qualifying transaction (the \"Transaction\") with 1926360 Alberta Ltd. dba Stigma Pharmaceuticals (\"Stigma\"). The Transaction constitutes a \"Qualifying Transaction\" as such term is defined by Policy 2.4 of the TSX Venture Exchange (the \"TSXV\") Corporate Finance Manual and was completed by way of three corner amalgamation pursuant to which Stigma amalgamated with a newly formed wholly owned subsidiary to form a new amalgamated company (\"Amalco\"), which now holds Stigma's assets as well as its wholly owned subsidiary. Amalco shall operate under the name \"Stigma Pharmaceuticals Inc.\"CanadaBis has obtained final approval to list its common shares on the TSXV as a Tier 2 Life Sciences Issuer. The common shares are expected to begin trading on the TSXV at the opening of markets on or about April 30th, 2019, under the symbol CANB.Following the Transaction, the Company will continue, through its subsidiaries, to operate the business of Stigma Grow and continue to be focused on producing high-quality and uniquely crafted products for the Alberta market. \"Our day-to-day focus will be on exploring a product and industry whose potential has gone unrealized for far too long, we are excited to help fill the void that we currently see in the Canadian cannabis market by offering better products to the local consumer while providing responsible and diversified investment to the industry on both a local and global scale\" said Travis McIntyre, President and CEO.The facility in Red Deer was awarded a Standard Cultivation License by Health Canada on March 8th of 2019. This cultivation license is one of only twelve administered in Alberta by Health Canada and will allow for the possession, production and distribution of cannabis in dried, fresh, plant and seed form. In addition, the Company has been awarded a Standard Processing License which will allow the Red Deer facility to process dried flower and manufacture cannabis oil products.Stigma Grow has the benefit of over three years of independent genetic research on 42 proprietary strains making them perfectly positioned to supply Albertans with a portfolio of uniquely developed craft cannabis pr...

More updates from Canadabis Capital, Inc.